Ranbaxy Laboratories Ltd has entered into the Canadian healthcare system with the launch of its wholly owned subsidiary, Ranbaxy Pharmaceuticals Canada Inc (RPCI). RPCI, the first Indian pharmaceuticals company with a presence in world's 8th largest pharmaceuticals market, will be engaged in the sale and distribution of affordable medicines in Canada.

According to a release, the company with global sales exceeding US$ 1.1 billion has been conducting clinical trials in Canada for the last five years and has already received approvals to sell eight products in the country in the anti-infective, diabetes and cardiovascular, space including Carvedilol, Ciprofloxacin, Citalopram, Domperidone, Lovastatin, Atenolol, Metformin and Zepiclone. RPCI will start shipping products in a few weeks. The company plans to launch a large number of important products in the next few years.